Medicare’s 2026 Sleep Apnea Crackdown: What Patients Need to Know

If you are a Medicare beneficiary who snores or has been diagnosed with obstructive sleep apnea, 2026 has brought a series of policy changes that directly affect your access to diagnosis and treatment. The Centers for Medicare and Medicaid Services implemented new prior authorization requirements for sleep-related procedures in six states, reduced reimbursement rates for sleep testing and PAP therapy codes by 2.5%, and imposed a 12-month validity window on sleep studies — meaning that a polysomnography result older than one year may no longer qualify you for equipment coverage.

These changes arrive at the worst possible time. The enhanced Affordable Care Act premium subsidies that had been buffering out-of-pocket costs for millions of Americans expired on December 31, 2025. For the roughly 22 million Americans on traditional Medicare who experience sleep-disordered breathing, navigating the new landscape means longer wait times, more paperwork, and significantly higher personal costs for the same treatments that were more accessible just months ago.

This guide breaks down exactly what changed, how it affects your options, and why an over-the-counter solution that requires no prescription, no sleep study, and no insurance approval may now be the most practical path for millions of snorers.

What Changed in Medicare Sleep Coverage for 2026

The Centers for Medicare and Medicaid Services (CMS) finalized several changes to sleep medicine coverage in its 2026 Physician Fee Schedule. The most impactful changes fall into three categories: prior authorization expansion, reimbursement reductions, and documentation requirements.

Prior authorization in six states. CMS expanded its prior authorization pilot program for durable medical equipment, including CPAP machines and related supplies, to six states. In these states, Medicare beneficiaries now need pre-approval before receiving a CPAP machine, replacement masks, tubing, or related equipment. The prior authorization process typically adds two to four weeks to the timeline between a physician order and equipment delivery, and denial rates in the initial pilot states ranged from 15 to 25% on first submission.

Reimbursement cuts of 2.5%. Sleep testing codes (both in-lab polysomnography and home sleep apnea tests) and PAP therapy management codes received a 2.5% reduction in reimbursement rates. While this may sound modest, it follows a pattern of cumulative cuts that have reduced sleep medicine reimbursement by more than 20% over the past decade. The practical effect is that fewer sleep labs can afford to accept Medicare patients, wait times for appointments increase, and some providers have exited the Medicare network entirely.

12-month sleep study validity. Sleep studies now expire after 12 months for the purposes of equipment qualification. Previously, a sleep study remained valid indefinitely as long as clinical circumstances had not changed materially. Under the new rules, a patient whose sleep study is older than one year must undergo a new study before qualifying for CPAP equipment or replacement supplies. Given that a single in-lab polysomnography can cost $1,000 to $3,000 before insurance, this represents a significant recurring expense.

The Real-World Cost Breakdown for Medicare Patients

Understanding the financial impact requires looking beyond the policy changes to the actual dollars that come out of your pocket. In 2026, Medicare Part B carries a $283 annual deductible and requires 20% coinsurance on most covered services with no out-of-pocket maximum. That 20% coinsurance applies to everything in the sleep apnea treatment pathway.

Sleep study costs. An in-lab polysomnography billed at $2,500 leaves you with a $500 coinsurance payment after the deductible is met. A home sleep apnea test is less expensive, typically $300 to $600, but the 20% coinsurance still applies, and not all patients qualify for home testing.

CPAP equipment costs. A new CPAP machine ranges from $500 to $1,500 depending on the model. Medicare covers 80% of the approved amount after your deductible, but the approved amount is often lower than the retail price, leaving you responsible for the gap. Auto-titrating CPAP machines (APAP), which are now the clinical standard, sit at the higher end of this range. With 20% coinsurance on a $1,200 approved amount, you are paying $240 out of pocket for the machine alone.

Ongoing supply costs. CPAP therapy is not a one-time purchase. Medicare covers replacement masks every three months, tubing every three months, filters monthly, and a new machine every five years. The coinsurance on these supplies adds up to $200 to $400 annually, and that assumes your replacement schedule is approved without delay under the new prior authorization requirements.

The total first-year cost. For a Medicare patient starting CPAP therapy in 2026, the realistic first-year out-of-pocket cost — including the sleep study, equipment, supplies, and specialist appointments — ranges from $800 to $1,500. For patients in prior authorization states who experience denials and must appeal, add weeks of untreated snoring and apnea plus the stress and time cost of navigating the appeals process.

The Prior Authorization Bottleneck

Prior authorization was designed to prevent unnecessary medical spending, but in practice it has become one of the most significant barriers to timely medical care in the United States. A Becker’s Healthcare analysis found that physicians spend an average of 14 hours per week on prior authorization paperwork, and that 34% of physicians report that prior authorization has led to a serious adverse event for a patient in their care.

For sleep apnea patients in the six pilot states, prior authorization creates a specific bottleneck. The typical pathway now looks like this: you see your primary care physician and describe your symptoms. Your physician orders a sleep study. The sleep study must be completed and interpreted. If the results indicate moderate-to-severe OSA with an apnea-hypopnea index above 15 (or above 5 with documented symptoms), your physician orders CPAP equipment. The DME supplier submits a prior authorization request to Medicare. Medicare reviews the request, which takes an average of 15 business days. If approved, the equipment is shipped. If denied, you must file an appeal.

From initial symptom report to equipment in hand, this process now takes an average of eight to twelve weeks in prior authorization states. For a condition that fragments your sleep every single night, disrupts your partner’s sleep, elevates your blood pressure, and increases your cardiovascular risk, three months of bureaucratic delay is not a minor inconvenience — it is a clinical problem.

The ACA Subsidy Expiration: A Compounding Factor

The enhanced ACA premium subsidies that were enacted during the pandemic and extended through 2025 expired on December 31, 2025. These subsidies had reduced the effective premium cost for marketplace insurance plans by an average of $700 per year per enrollee, making it more affordable for people in the coverage gap between Medicaid eligibility and traditional Medicare enrollment to maintain comprehensive health insurance.

The expiration affects sleep apnea patients in two ways. First, some patients who had been managing their sleep apnea through marketplace plans with sleep medicine coverage now face higher premiums and may choose less comprehensive plans that exclude or limit sleep-related services. Second, the general tightening of healthcare budgets at the federal level has contributed to the reimbursement cuts and prior authorization expansions that affect Medicare directly.

The combined effect is a healthcare environment in which getting diagnosed and treated for sleep-disordered breathing is more expensive, more time-consuming, and more bureaucratically complex than at any point in the past decade. And that creates a critical question for the millions of people who snore but may not have severe enough apnea to justify the cost and hassle of the clinical pathway: is there a simpler option?

The OTC Alternative: No Prescription, No Sleep Study, No Insurance

For primary snoring and mild sleep-disordered breathing, there is a category of solution that sidesteps every single barrier described above: over-the-counter oral appliances. These devices require no physician visit, no sleep study, no prior authorization, no insurance claim, and no waiting period. You order one, it arrives, you custom-fit it at home, and you use it that night.

The contrast with the CPAP pathway is stark. A CPAP alternative like the Snorple mouthpiece costs $69 — less than the Medicare coinsurance payment on a single sleep study. It uses mandibular advancement technology to gently reposition the lower jaw forward, maintaining an open airway during sleep. The same mechanism of action is used by custom dental appliances that cost $1,500 to $3,000 and require a dentist visit and dental impressions.

This is not to suggest that everyone with sleep apnea should skip clinical evaluation. If you experience witnessed breathing pauses during sleep, wake up gasping or choking, suffer from severe daytime sleepiness that impairs your ability to drive or work, or have been told you stop breathing at night, you need a proper sleep evaluation regardless of the cost or hassle. Moderate-to-severe obstructive sleep apnea carries serious cardiovascular, metabolic, and cognitive risks that require medical management.

But here is the reality that the insurance system obscures: the majority of people who snore do not have moderate-to-severe sleep apnea. Most snorers fall into the categories of primary snoring or mild OSA, conditions for which the American Academy of Sleep Medicine now recognizes oral appliances as a first-line treatment. For these patients, the clinical pathway — with its months of delays, hundreds of dollars in coinsurance, and prior authorization hurdles — may be solving the wrong problem in the most expensive way possible.

A Practical Decision Framework for Medicare Patients

If you are on Medicare and you snore, here is a practical framework for deciding how to proceed.

If you suspect moderate-to-severe sleep apnea — meaning you experience breathing pauses, gasping awakenings, severe daytime fatigue, or your partner reports that you stop breathing during sleep — pursue the clinical pathway despite the barriers. Request a home sleep apnea test first, as it is less expensive than in-lab polysomnography and may be sufficient for diagnosis. Be prepared for the prior authorization timeline if you are in one of the six pilot states, and consider filing your request early to minimize delays.

If you snore but do not have apnea symptoms — meaning your primary complaint is loud snoring that disturbs your partner, morning dry mouth or sore throat, or mild daytime tiredness — an OTC oral appliance is the most cost-effective and time-efficient first step. At $69, it costs less than a single specialist copay. If it resolves your snoring, you have saved yourself months of appointments and hundreds of dollars. If it does not fully resolve the issue, you have lost nothing and gained information that will help your physician if you decide to pursue clinical evaluation later.

If you are currently on CPAP and struggling with compliance — and data suggests that fewer than half of CPAP users maintain adequate compliance — talk to your sleep physician about transitioning to an oral appliance. The growing trend of patients switching from CPAP to oral appliances reflects both the compliance challenges inherent to PAP therapy and the improving evidence base for mandibular advancement devices.

Understanding the full cost of snoring goes beyond equipment prices. Untreated snoring and sleep apnea carry downstream costs in cardiovascular disease, metabolic dysfunction, workplace accidents, and reduced quality of life. The cheapest option is not always the best option — but in this case, the most affordable OTC solution also happens to be the most accessible and, for primary snoring, the most proportionate response to the problem.

How to Maximize Your Medicare Sleep Benefits

If you do pursue the clinical route, here are specific steps to minimize cost and delay.

Request a home sleep test first. Home sleep apnea tests cost a fraction of in-lab polysomnography and are accepted by Medicare for most patients without complex comorbidities. Ask your physician specifically about home testing before agreeing to an in-lab study.

Verify your provider is in-network. With reimbursement cuts driving some sleep specialists out of the Medicare network, confirm network status before your appointment to avoid surprise bills.

Keep your sleep study current. Under the new 12-month validity window, schedule your equipment order promptly after receiving study results. Waiting too long means repeating the study at additional cost.

Appeal denials. If your prior authorization is denied, appeal immediately. First-level appeals overturn denials in approximately 40% of cases for DME, and the process, while frustrating, is worth pursuing if you qualify for coverage.

Explore Medigap and Medicare Advantage options. Supplemental Medigap policies can cover the 20% coinsurance that traditional Medicare leaves uncovered. Medicare Advantage plans may offer different coverage structures for sleep medicine services. Compare plans during open enrollment with sleep coverage specifically in mind.

The insurance coverage landscape for snoring devices is complex and changing. But the trend is clear: the administrative and financial barriers to clinical sleep treatment are growing, and for the majority of snorers whose problem does not rise to the level of severe sleep apnea, an affordable over-the-counter mouthpiece offers a path that bypasses every single barrier.

The ongoing CPAP recall situation adds yet another layer of complexity for patients who were already navigating a difficult coverage landscape. For those affected, oral appliances represent not just a cost-effective alternative but often the only immediately available option.